- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objectives: This study is aimed to evaluate the protective effects of GGX on lung injury of Chronic Obstructive Lung Disease (COPD) mice model. Materials and Methods: C57BL/6 mice were challenged with lipopolysaccharide (LPS) and cigarette smoke extract (CSE) and then treated with vehicle only (Control group), dexamethasone 3 ㎎/㎏ (Dexa group), gam-gil-tang 200 ㎎/㎏ (GGT group), GGX 100, 200, and 400 ㎎/㎏ (GGX group). After sacrifice, its bronchoalveolar lavage fluid (BALF) or lung tissue was analyzed with cytospin, Enzyme-Linked Immunosorbent Assay (ELISA), real-time polymerase chain reaction (PCR) and hematoxylin & eosin (H&E), and Masson’s trichrome staining. Results: In the COPD model, GGX significantly inhibited the increase of neutrophils, TNF-α, IL-17A, CXCL-1, MIP2 in BALF and TNF-α, IL-1β, IL-10 mRNA expression in lung tissue. It also decreased the severity of histological lung injury.
1. Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY Lee JH, et al. (2018). COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis (Seoul), 81:261–73.
2. Barnes PJ, Shapiro SD, Pauwels RA. (2003). Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J, 22(4):672-88.
3. Kim IA, Park YB, Yoo KH. (2004). Pharmacotherapy for chronic obstructive pulmonary disease. J Korean Med Assoc, Sep;61(9):545-551.
4. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. (1994). Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA, 272:1497-505.
5. Singh S, Amin AV, Loke YK. (2009). Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med, 169:219-29.
6. Barnes PJ. (2013). New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov, 12(7):543-59.
7. Lee ES, Han JM, Kim MH, Namgung U, Yeo Y, Park YC. (2013). Effects of inhalable microparticles of Socheongryong-tang on chronic obstructive pulmonary disease in a mouse model. J Korean Med, 34(3):54-68.
8. Lee JG, Yang SY, Kim MH, Namgung U, Park YC. (2011). Protective effects of Socheongryong-tang on elastase-induced lung injury. J Korean Oriental Med, 32(4):83-99.
9. Kim Y, Yang SY, Kim MH, Namgung U, Park YC. (2011). Effects of Saengmaekcheongpye-eum on LPS-induced COPD model. Korean J Oriental Int Med, 2011;32(2):217-31.
10. Kim HW, Yang SY, Kim MH, Namgung U, Park YC. (2011). Protective effects of Maekmundong-tang on elastase-induced lung injury. J Korean Oriental Med, 32(2):63-78.
11. Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S, et al. (2012). Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med, 2012:769830.
12. Han JM, Yang WK, Kim SH, Park YC. (2015). Effects of Sagan-tang and individual herbs on COPD mice model. J Korean Med Soc Herb Formula Study, 23(2):171-87.
13. Park JJ, Yang WK, Lyu YR, Kim SH, Park YC. (2019). Inhibitory effects of SGX01 on lung injury of COPD mice model. Korean J Int Korean Med, 40(4):567-81.
14. Yang WK, Lyu YR, Kim SH, Park YC. (2018). Effects of GHX02 on Chronic Obstructive Pulmonary Disease Mouse Model. J Korean Med, 39(4):126-35.
15. Kim SH, Hong JH, Yang WK, Geum, et al. (2020). Herbal combinational medication of Glycyrrhiza glabra, Agastache rugosa containing Glycyrrhizic acid, Tilianin inhibits Neutrophilic lung inflammation by affecting CXCL2, Interleukin-17/STAT3 signal pathways in a murine model of COPD. Nutrients, 12(4), 926.
16. Yang, L., Li, J., Li, Y., Tian, Y., Li, S., Jiang, et al. (2015). Identification of metabolites and metabolic pathways related to treatment with Bufei Yishen formula in a rat COPD model using HPLC Q-TOF/MS. Evidence-Based Complementary and Alternative Medicine, 2015.
17. Hwang DY. (1986). Bang-yak-hap-pyeon. Seoul:Namsandang, p.240.
18. Lyu YR. (2020). Inhibitory effects of GGX in a particulate matter-induced lung injury mouse model. doctoral dissertation, Daejeon university.
19. Hong HW. (2011). The Effects of Kamgiltang on Passive Smoking in Rats, doctoral dissertation, Dong-eui University.
20. Mizutani N, Fuchikami J, Takahashi M, Nabe T, Yoshino S, Kohno S. (2009). Pulmonary emphysema induced by cigarette smoke solution and lipopolysaccharide in guinea pigs. Biol Pharm Bull, 32(9):1559-64.
21. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. (2006). Chronic obstructive pulmonary disease: current burden and future projections. Eur Rspir J, 27(2):397-412.
22. Mathers CD, Loncar D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 3(11):e442
23. An TJ Yoon HK. (2018). Prevalence and socioeconomic burden of chronic obstructive pulmonary disease. J Korean Med Assoc, 61(9):533-8.
24. GBD 2015 Chronic Respiratory Disease Collaborators. (2017). Global, regional, and national deaths, prevalence, disabilityadjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 5(9):691-706.
25. Jung YM, Lee H. (2011). Chronic obstructive pulmonary disease in Korea: Prevalence, risk factors, and quality of life. J Korean Acad Nurs, 41(2):149-56.
26. Ministry of Gender Equality & Family (MOGEF). (2014). 2014 Comprehensive survey on the contact with the harmful environment for youth. Available at: URL: http://www.mogef. go.kr. Accessed April 1.
27. Yoon J, Seo H, Oh IH, Yoon SJ. (2016). The Non-Communicable Disease Burden in Korea:Findings from the 2012 Korean Burden of Disease Study. J Korean Med Sci, Nov;31(Suppl 2):S158-S167.
28. Park SK. (2002). Chronic obstructive pulmonary disease - definition, severity, risk factors, etiology, pathology, diagnosis. J Korean Med, 63(2):389-99.
29. Lurwidya F, Damayanti T, Yunus F. (2016). The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis(Seoul), 79(1):5-13.
30. Lee S, et al. (2007). Antielastin autoimmunity in tobacco smokinginduced emphysema. Nature Med, 13:567-569.
31. Yoo CG. (2009). Pathogenesis and pathophysiology of COPD. Korean J Med, 77(4): 383-400.
32. Barnes PJ. (2004). Macrophages as orchestrators of COPD. COPD, 1:59-70.
33. Majo J, Ghezzo H, Cosio MG. (2001). Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J, 17:946-53.
34. Barnes PJ. (2008). The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest, 118(11):3546-56.
35. Rovina N, Koutsoukou A, Koulouris NG. (2013). Inflammation and immune response in COPD: where do we stand?, Mediators Inflammation, 2013:413735.
36. Herbology Editorial Committee of Korean Medicine schools. (1991). Boncho-hak. Seoul:Younglimsa, 124-5, 136-7, 214-5, 448-9, 534-5, 580-1, 588-9.
37. Park YC, Jin M, Kim SH, Kim MH, et al. (2014). Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. Journal of Ethnopharmacology, 151(1), 123-130.
38. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, et al. (1998). Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med, 158(4):1277-85.
39. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, et al. (2001). Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163(2):349-55.
40. Deveci Y, Deveci F, Ilhan N, Karaca I, Turgut T, Muz MH. (2010). Serum ghrelin, IL-6 and TNF-α levels in patients with chronic obstructive pulmonary disease. Tuberk Toraks, 58(2):162-72.
41. Traves SL, Donnelly LE. (2008). Th17 cells in airway diseases. Curr Mol Med, 8(5):416-26.
42. Levänen B, Glader P, Dahlén B, Billing B, Qvarfordt I, Palmberg L, et al. (2016). Impact of tobacco smoking on cytokine signaling via interleukin-17A in the peripheral airways. Int J Chron Obstruct Pulmon Dis, 11:2109-16.
43. Lukacs NW, Hogaboam CM, Kunkel SL. (2005). Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy, 4(3):313-7.
44. Traves SL Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. (2002). Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax, 57(7):590–5.
45. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, et al. (2003). Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167(1):24-31.